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Abstract
Purpose IgG4-related disease (IgG4-RD) is an increasingly
recognized clinicopathological disorder with immune-
mediated inflammatory lesions mimicking malignancies. A
cohort study was prospectively designed to investigate the
value of 18F-fluorodeoxyglucose (FDG) positron emission
tomography/computed tomography (PET/CT) in characteriz-
ing IgG4-RD.
Methods Thirty-five patients diagnosed with IgG4-RD accord-
ing to the consensus criteria were enrolled with informed con-
sent. All patients underwent baseline 18F-FDG PET/CT evalu-
ation. Among them, 29 patients underwent a second 18F-FDG
PET/CT scan after 2 to 4 weeks of steroid-based therapy.
Results All 35 patients were found with 18F-FDG-avid hyper-
metabolic lesion(s); 97.1 % (34/35) of these patients showed
multi-organ involvement. Among the 35 patients, 71.4 %
(25/35) patients were found with more organ involvement
on 18F-FDG PET/CT than conventional evaluations including
physical examination, ultrasonography, and computed tomog-
raphy (CT). 18F-FDG PET/CT demonstrated specific image
characteristics and pattern of IgG4-RD, including diffusely
elevated 18F-FDG uptake in the pancreas and salivary glands,
patchy lesions in the retroperitoneal region and vascular wall,
and multi-organ involvement that cannot be interpreted as
metastasis. Comprehensive understanding of all involvement
aided the biopsy-site selection in seven patients and the re-
canalization of ureteral obstruction in five patients. After 2 to
4 weeks of steroid-based therapy at 40 mg to 50 mg predni-
sone per day, 72.4 % (21/29) of the patients showed complete
remission, whereas the others exhibited > 81.8 % decrease in
18F-FDG uptake.
Conclusion F-FDG PET/CT is a useful tool for assessing
organ involvement, monitoring therapeutic response, and
guiding interventional treatment of IgG4-RD. The image pat-
tern is suggested to be updated into the consensus diagnostic
criteria for IgG4-RD.
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Introduction
IgG4-related disease (IgG4-RD) has been an increasingly
recognized clinical entity in recent years [1–3]. As an
immune-mediated inflammatory disease characterized by
swe l l i ng l e s i on s w i t h s t o r i f o rm f i b r o s i s a nd
lymphoplasmacytic infiltration enriched with IgG4-positive
plasma cells, IgG4-RD have been found in multiple organs/
tissues, including the pancreas (also known as autoimmune
pancreatitis, AIP), pancreatobiliary tract, lacrimal gland, sali-
vary gland, lung, retroperitoneal region, and kidney [4].
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Although several molecular and cellular mechanisms have
been found to be correlated with IgG4-RD, the etiology of
the disease is still unknown [5, 6]. AIP is a major and well-
studied constituent of IgG4-RD. In 2003, multiple
extrapancreatic lesions with rich infiltration of IgG4-positive
plasma cells were reported; these lesions are similar to the
pancreatic lesions in patients with AIP [7, 8]. Since then,
many medical conditions, such as sclerosing sialadenitis, ret-
roperitoneal fibrosis, and lymphoplasmacytic aortitis, were
subsequently reported to be associated with AIP, indicating
that these diseases may be part of a spectrum of clinical
entities not yet well recognized [9–11]. A new clinicopatho-
logical disorder called IgG4-related disease was then proposed
[12, 13]. However, many details about the gradually recog-
nized clinical entity remain unclear. Inadequate understanding
may cause misdiagnosis of the disease as malignancies. Such
misunderstanding can cause high psychological pressure in
the patients, excessive examinations, and even unnecessary
surgical intervention when the condition can actually be cured
by corticosteroid-based treatment [14, 15].
Integrated positron emission tomography and computed
tomography (PET/CT) with 18F-fluorodeoxyglucose (18F-
FDG) as the tracer provides metabolic information on the
entire body; 18F-FDG PET/CT has been broadly used in the
diagnosis, staging, response evaluation, and relapse monitor-
ing of various types of malignancies [16]. 18F-FDGPET/CT is
also used to assess both infectious and non-infectious inflam-
matory conditions [17]. A few recent case reports and retro-
spective analysis have preliminarily indicated possible value
of 18F-FDG PET/CT in IgG4-RD evaluation [18–25]. A pro-
spective cohort study was then designed to investigate the
efficacy of 18F-FDG PET/CT in characterizing this tumor-




This study was approved by the Institute Review Board of
Peking Union Medical College Hospital (S-442) and regis-
tered online at the NIH ClinicalTrial.gov (NCT01665196).
From May 2011 to December 2012, a total of 35 patients (M
23, F 12, aged 57±12 years), mainly presented with
Mikulicz’s disease (14/35, 40.0 %), autoimmune pancreatitis
(12/35, 34.3 %), and retroperitoneal fibrosis (8/35, 22.9 %),
were recruited with written informed consent. All patients
were finally diagnosed with IgG4-RD according to the 2011
consensus criteria of IgG4-RD [26, 27]. The serum IgG4 level
ranged from 163 mg/dl to 6,860 mg/dl (mean ± standard
deviation: 1,649±1,756, normal < 135). Twenty-one
(60.0 %) patients presented with allergies. Twenty (57.1 %)
patients had a pathological diagnosis. The demographics of
the patients are listed in Table 1.
PET/CT scans
All patients were instructed to avoid strenuous work or exer-
cise for at least 24 h, and to fast more than 4 h before
intravenous injection of 18F-FDG at a dosage of 5.55 MBq
(0.15 mCi) per kilogram body weight. The patients then rested
in a warm, darkened room for nearly 1 h. After emptying the
bladder, an acquisition was performed frommid-thigh to skull
base (five to six bed positions, 2 min per bed) using a Siemens
Biograph 64 Truepoint TrueV PET/CT scanner. Twenty-nine
(82.9 %) patients also underwent a second PET/CT scan 2 to
4 weeks after the steroid-based treatments at a dosage of
40 mg to 50 mg prednisone per day (Table 1).
Data analysis
The attenuation-corrected PET images and CT images were
transferred to a Siemens MMWPmulti-modality workstation.
The visual analysis of PET/CT characteristics and pattern was
done by three experienced nuclear medicine physicians and
two rheumatologists through consensus reading using TrueD
software (Siemens Medical Solution). The standardized up-
take values (SUV) of the lesions were measured by the same
nuclear medicine physician using the volume of interest (VOI)
method and a unified standard. The images were transferred to
an AW workstation (GE Healthcare) and then loaded onto a
PETVCAR software (GEHealthcare) for response evaluation
according to the PET Response Evaluation Criteria in Solid
Tumor (PERCIST, version 1.0) [28]. The SUV corrected for
lean body mass (SUL) and the total lesion glycolysis (TLG)
were measured over the VOIs placed over the “hot” lesions of
the involved organs or tissues. The changes in 18F-FDG
uptake between the baseline and the follow-up scans were
automatically calculated by the software, and finally reported
as complete metabolic response, partial metabolic response,
stable metabolic disease, or progressive metabolic disease
according to the PERCIST 1.0.
Statistical analysis
Continuous variables were summarized as means ± standard
deviation; categorical variables were described in numbers
and percentages. Continues variables between two groups
were compared using student t test. The correlation between
TLG and IgG4 level was evaluated by Pearson correlation
coefficient. All tests were two-tailed with the significant level
of 0.05. The analysis was carried out with the use of Prism 5.0.
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Results
Assessing organ involvement
All 35 patients were found with 18F-FDG-avid lesion(s) relat-
ed to the disease. Thirty-four (97.1 %) patients showed lesions
in more than one organ and 24 (68.6 %) had involvement in
three or more organs. The most commonly involved organs
were lymph nodes (30/35, 85.7 %), salivary glands (23/35,
65.7 %), and pancreas (18/35, 51.4 %). The involved organs
or tissues are shown in Fig. 1 in descending order. In a total of
131 organ involvement in the 35 patients, 18F-FDG PET/CT
additionally detected 40.5 % (53/131) organ involvement in
71.4 % (25/35) patients, including 100 % (8/8) of the aorta
involvement, 63.3 % (19/30) of the lymph node involvement,
34.8 % (8/23) of the salivary gland involvement. Nine of ten
patients enrolled with single organ disease were finally found
with multi-organ involvement. Figure 1 illustrates the addi-
tional findings of 18F-FDG PET/CT in each organ, whereas
the additional organ involvement demonstrated by 18F-FDG
PET/CT in each patient is listed in Table 1.
Characterizing image pattern
The lesions varied from diffuse infiltration to patchy or nod-
ular forms, with the average SUV ranging from 1.1 to 8.3 (3.2
±1.4). Characteristic 18F-FDG distributions were observed in
the PET/CT images of these patients. Table 2 summarizes the
characteristics that we considered to be useful for indicating
IgG4-RD rather than malignancies or other benign diseases.
For each characteristic, the level of confidence for IgG4-RD
indication was rated as strong, moderate, or weak according to
our experiences in interpreting the images of IgG4-RD pa-
tients and our routine clinical patients, mainly by comparing
with cancer patients. The most important characteristics were
classified into four categories. The first category was diffusely
elevated 18F-FDG uptake in the exocrine organ, such as sali-
vary glands, pancreas, and prostate gland (Fig. 2). The second
was patchy 18F-FDG-avid hypermetabolic lesions, mainly
involving the retroperitoneal region, vascular wall, bile duct,
lungs, liver, and kidneys (Fig. 3). The third was extensive
distribution of multiple lesions that could not be interpreted as
common metastasis of malignancies. The last was rapid and
significant response to steroid-based treatment.
Guiding biopsy and intervention
In seven cases, the new findings on 18F-FDG PET/CT resulted
in the reselection of biopsy site to more accessible lesions,
such as peripheral lymph nodes and submandibular gland.
Figure 2 shows one of the biopsy results with typical
inflammatory-cell infiltration consisting of a large amount of
IgG4-positive plasma cells.
18F-FDGPET/CTalso showed acute ureteral obstruction in
five of the 12 patients with retroperitoneal fibrosis. The com-
plete obstruction was characterized by hydronephrosis with-
out radioactivity in the urine, whereas the partial obstruction
had intense radioactivity in the urine retention. These findings
opened the opportunity for timely recanalization of the ureters
to avoid irreversible renal failure (Fig. 3).
Evaluating treatment response
All 29 cases that underwent PET/CT follow-ups 2 to 4 weeks
after treatment showed a remarkable decrease in 18F-FDG
uptake following steroid-based therapy at a dosage of 40 mg
to 50 mg prednisone per day. A PET VCAR analysis reported
complete metabolic remission in 21 cases (72 %), whereas the
Fig. 1 List of involved organs/
tissues in the 35 IgG4-RD
patients in descending order and
the contribution of 18F-FDG PET/
CT to the detection of
involvement. Blue bar: total
number of cases with the organs/
tissues involved; Red Bar: the
amount of involvement
additionally detected by 18F-FDG
PET/CT
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other eight cases showed partial metabolic response with an
81.8 % to 98.9 % (89.0 %±6.4 %) decrease in TLG. Clinical
symptoms and signs of the patients, including the allergies,
were significantly relieved. Serum IgG4 levels decreased only
in 88.6 % (31/35) cases and with less significance (Fig. 4). No
significant correlation was found between the TLG and the
IgG4 level in these patients (r=0.37, P=0.06).
Discussion
Many questions about IgG4-RD, an emerging clinical entity
most probably mediated by immune reaction, remain unre-
solved [1–3]. First of all, the diagnosis of IgG4-RD remains a
challenge in clinical practice. In 2011, comprehensive diag-
nostic criteria for IgG4-RD were proposed, in which an abun-
dant IgG4 positive cell infiltration (> 40 % of IgG positive
plasma cells being IgG4 positive and > 10 IgG4 positive cells
per high power field) in biopsy sample and an elevated serum
IgG4 level over 135 mg/ml were emphasized [26]. These
statements represent a major progress in the diagnosis
of IgG4-RD. However, biopsy specimens are sometimes
difficult to obtain and not always adequate for diagnosis
[29]; serum IgG4 levels may also be normal in some
patients with IgG4-RD, whereas an elevated serum IgG4
level can be encountered in a wide array of disorders,
including allergic diseases, Castleman’s disease, and
lymphoma [30–32].
In addition to the histopathological diagnosis and serolog-
ical findings, IgG4-RD is also characterized by multi-organ
involvements with special manifestations [1–3]. The disease
has been recognized as a systemic immune-mediated inflam-
matory condition since 2003, when extrapancreatic lesions
were identified with infiltration of IgG4-positive plasma cells
in patients with AIP [7, 8]. Since then, IgG4-RD has been
found in almost every organ [9–13]. Therefore, we believe
non-invasive imaging characteristics should also serve as an
important tool in the diagnosis of IgG4-RD, and a systematic,
comprehensive understanding of the distribution information
of IgG4-RD is vital for its diagnosis, staging, and treatment.
However, conventional imaging methods, such as ultrasonog-
raphy, CT, and magnetic resonance imaging (MRI), have a
limited value in the provision of a comprehensive evaluation
of the disease, although some characteristics of diffuse and
focal infiltration are considered specific in some organs, such
as the pancreas [33]. Whereas 18F-FDG PET/CT, which holds
an advantage in providing metabolic information of the whole
body in one scan, may be a valuable tool to evaluate the
Table 2 Summary of the image characteristics that form the pattern of IgG4-related disease on 18F-FDG PET/CT
Image characteristics Confidence for indication of IgG4-RD
1. Diffusely elevated 18F-FDG uptake in organs, mainly involving salivary glands, pancreas, and prostate
(1) Evenly, symmetrically distributed 18F-FDG uptake in the salivary glands without signs of infection Strong
(2) Diffusely enlarged pancreas with moderate to intense 18F-FDG uptake without pancreaticobiliary
duct obstruction
Strong
(3) Diffusely enlarged prostate with moderate to intense 18F-FDG uptake Moderate
(4) Broadly involved lymph nodes with moderate to intense 18F-FDG uptake Moderate
2. Patchy 18F-FDG-avid lesion without signs of infection, mainly involving aorta wall, retroperitoneal region,
pancreas, bile duct, liver, kidney, and lung
(5) Patchy thickness of aorta wall with moderate to intense 18F-FDG uptake not limited to the vascular intima Strong
(6) Patchy retroperitoneal lesion with moderate to intense 18F-FDG uptake Strong
(7) Patchy pancreatic lesion Moderate
(8) Patchy bile duct lesion Moderate
(9) Patchy liver lesion Moderate
(10) Patchy lesions in the enlarged irregular kidneys Moderate
(11) Patchy lung lesion Weak
(12) Patchy pleural lesion Weak
(13) Patchy pericardial lesion Weak
3. Multi-organ involvement, including the following characteristics besides the above-mentioned
(14) Pancreas nodule or mass Weak
(15) Kidney nodule or mass Weak
(16) Lung nodule(s) Weak
4. Rapid, significant response to steroid-based treatment
(17) The 18F-FDG-avid lesions had more than 80 % decrease of activity after 2 to 4 weeks of
steroid-based treatment at a dosage of 40 mg to 50 mg prednisone per day
Strong
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systemic inflammatory disease and reflect the involvements in
each organ and the activity in each lesion, as well [16, 17].
Recently, several case reports and a retrospective analysis
have preliminarily indicated a possible value of 18F-FDG
PET/CT in evaluation of patients with IgG4-RD [18–25].
Most of these reports focused on the differentiation of AIP
from pancreatic cancer. Although there was no significant
difference of pancreatic 18F-FDG uptake between patients
with AIP and patients with pancreatic cancer, certain patterns,
including multiple foci in the pancreas, 18F-FDG uptake of the
hilar lymph node, and extrapancreatic uptakes, were believed
to be indications of AIP [24, 25]. A recent retrospective
analysis also showed that multi-organ involvement was found
in 84.2 % (16/19) patients [18]. In our prospective study with
a relatively larger cohort of patients, multi-organ/tissue in-
volvement was found in 97.1 % (34/35) patients; 18F-FDG
PET/CT detected significantly more lesions in 71.4 % of the
patients than the conventional imaging methods; and 90 %
patients enrolled with single organ disease were finally found
with multi-organ involvement. Therefore, our study confirms
that 18F-FDG PET/CT can define more lesions than conven-
tional imaging methods by providing a whole-body metabolic
condition and morphological abnormality; thereby, it can
serve as a sensitive tool in assessing organ involvement and
disease distribution.
Based on this prospective study, we further analyzed the
imaging characteristics of 18F-FDG PET/CT in IgG4-RD
patients by comparing them with our routine patients (mostly
with malignancies). As listed in Table 2, the strongest indica-
tions that we believe establish an IgG4-RD diagnosis include:
1) evenly, symmetrically distributed 18F-FDG uptake in the
salivary glands without signs of infection; 2) diffusely en-
larged pancreas with moderate to intense 18F-FDG uptake
without pancreaticobiliary duct obstruction; 3) patchy
Fig. 2 A 54-year-old man with IgG4-related disease showedmulti-organ
involvement (a whole-body view; b salivary glands; c pancreas; d pros-
tate), significant response after two weeks of steroid-based treatment (e–
h), and characteristic immunohistochemical stains of submandibular
gland specimen (iHE stain; j CD38-positive plasma cells; k IgG-positive
cells; l IgG4-positive cells. The IgG4-positive cells were > 60 % of the
IgG-positive cells)
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thickness of aorta wall with moderate to intense 18F-FDG
uptake not limited to the vascular intima; 4) patchy retroper-
itoneal lesion with moderate to intense 18F-FDG uptake; and
5) the 18F-FDG-avid lesions had more than 80 % decrease of
activity after 2 to 4 weeks of steroid-based treatment at a
dosage of 40 mg to 50 mg prednisone per day. Although none
of these characteristics alone is specific enough for diagnosis
of IgG4-RD, co-existence of several characteristics simulta-
neously may strongly indicate the disease.
Another possible contribution of 18F-FDG PET/CT in di-
agnosis of IgG4-RD is its value in helping the selection of a
minimal and adequate biopsy site [21, 34]. In contrast to
conventional imaging techniques, 18F-FDG PET/CT reflects
glucose metabolism and provides disease activity of lesions.
Fig. 4 Changes in total lesion
glycolysis (TLG) demonstrated
by 18F-FDG PET/CT (a) were
more remarkable than the changes
in serum IgG4 level (b) after 2 to
4 weeks of steroid-based
treatment
Fig. 3 18F-FDG PET/CT guided the timely ureter recanalization in an
IgG4-RD patient with retroperitoneal fibrosis and aorta involvement. The
enlarged right renal pelvis with radioactive urine retention indicated
severe ureteral obstruction, whereas the left side without radioactivity
indicated complete obstruction (a and b). After D-J tube cannulation, the
renal function was recovered bilaterally (c and d); the intense-uptake
lesions were smaller and the intensity was significantly lower in response
to the steroid treatment. The arrows show the aorta involvement beside
the retroperitoneal fibrosis (e, f), which has a complete response to
steroid-based treatment (g, h)
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Therefore, 18F-FDG PET/CT can be a useful tool to localize
an appropriate biopsy site, especially in cases with a negative
result using conventional imaging methods, or those with
multiple lesions but without functional preference. In our
study, biopsy was performed in 20 patients. Among them,
new findings of 18F-FDG PET/CT resulted in reselection of
biopsy sites in seven patients. Here, we believe that 18F-FDG
PET/CT has played an important role in selection of biopsy
site, and further infer that a PET/CT guided biopsy will
decrease the false-negative rate by providing a more accessi-
ble lesion with high metabolic activity.
Although there is no standardized therapeutic protocol for
IgG4-RD, several points about treatment are clear. Without a
fully established evaluation system, it is hard to outline the
severity of the disease in an individual patient. Therefore, the
intensity of a treatment is based on experience, mainly accord-
ing to the clinical manifestations rather than the severity and
extent of the disease. Steroid-based therapy is considered as
the first-line therapy to both pancreatic and extrapancreatic
lesions, and seems to be effective in the majority of the
patients [35]. When vital organs are involved or life-
threatening complications happen, aggressive treatment is
need. For example, in patients with aorta involvement, the
IgG4-related aortitis can finally lead to aortic aneurysms,
which is a lethal condition, and a surgical procedure may be
required [36, 37]. However, aortitis is usually diagnosed when
severe complications occur, since it is asymptomatic at the
early stage when it can be treated simply by using steroids. In
our study, none of the patients had been found with aorta
involvement before the 18F-FDG PET/CT scan; however,
eight patients were proved to have aortic involvement by
18F-FDG PET/CT scans. Moreover, 18F-FDG PET/CT
showed acute ureteral obstruction in five of the 12 patients
with retroperitoneal fibrosis, which allowed opportunities for
recanalization of the ureters to avoid irreversible renal failure.
Therefore, our study showed that 18F-FDGPET/CTcould be a
useful tool in unsealing the insidious conditions that might
lead to severe complications at the early stage.
On the other hand, there is still no standardized method to
evaluate the activity of the disease and response to treatment.
Laboratory tests, such as elevated serum IgG4 or IgG, com-
plement consumption, erythrocyte sedimentation rate, and
recently, the B cell-activating factor of the tumor necrosis
factor family (BAFF) and a proliferation-inducing ligand
(APRIL) , together with imaging findings, are considered to
be associated with disease activity [35, 38, 39]. However, as
mentioned above, some serum markers such as IgG4 level
may be normal in some patients, and conventional imaging
methods also have limitations in monitoring the disease since
they only reflect morphological features. Recently, a respond-
er index for IgG4-RD was proposed, which emphasized the
subjective evaluation of lesions activity as well as serum IgG4
level [40]. Although this effort has made it easier for
physicians to make a comprehensive evaluation, there is still
a challenge to monitor the response to treatment. In our
prospective study, most of the 29 patients who underwent
follow-up 18F-FDG PET/CT had an early, complete metabolic
response to steroid-based therapy, which was in accordance
with other reports [18, 23, 38]. In addition, we further ana-
lyzed the changes between the baseline and follow-up scans,
and classified response levels according to the PET Response
Evaluation Criteria in Solid Tumor (PERCIST, version 1.0).
With only 2 to 4 weeks of steroid-based treatment, 72.4% (21/
29) patients showed complete remission and the others also
exhibited a ≥ 81.8 % decrease of TLG, whereas the serum
IgG4 levels decreased in only 88.6 % cases and with much
less significance. The prompt, quantitative response informa-
tion provided by 18F-FDG PET/CT may be useful for evalu-
ation of new treatment methods for IgG4-RD [41], although
further studies are needed to exclude possible overestimation
of therapeutic response. The early, rapid response to steroid-
based treatment can also be used to verify the diagnosis and
exclude possible concurrent malignancies [42, 43].
So far, 18F-FDG PET/CT has not achieved its rightful place
in the consensus diagnostic criteria for IgG4-RD [26]. The
above-mentioned data suggest that 18F-FDG PET/CT is an
essential tool in many aspects of the diagnosis and treatment
of IgG4-RD. To the best of our knowledge, this work is
the first prospective study that uses a relatively large
cohort of IgG4-RD patients to comprehensively clarify
the usefulness of 18F-FDG PET/CT in evaluating
multiorgan involvement, monitoring treatment response,
and guiding biopsy and interventions.
The main limitation of this study is that only definitely
diagnosed IgG4-RD cases were included in the analysis. As
shown in Table 1, most patients in this group presented with
Mikulicz’s disease (40.0 %), autoimmune pancreatitis
(34.3 %), or retroperitoneal fibrosis (22.9 %). Such conditions
might result in selection bias, because these kinds of patients
were more easily diagnosed to have IgG4-RD and readily
enrolled, whereas the rare or complicated conditions of
IgG4-RD, such as those with normal IgG4 levels, were ex-
cluded. Therefore, this study represents a preliminary investi-
gation of the characteristics of IgG4-RD using 18F-FDG PET/
CT. In future studies, patients suspected to have IgG4-RD,
especially those with malignancies, such as lymphoma with
elevated serum IgG4 levels, should be included to determine
the diagnostic accuracy of 18F-FDG PET/CT in IgG4-RD.
Conclusions
In conclusion, whole body 18F-FDG PET/CT can provide a
comprehensive view of the organs/tissues involved in IgG4-
RD, and detect a larger number of lesions than conventional
imaging methods such as ultrasonography and CT. The image
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characteristics or pattern of IgG4-RD observed on 18F-FDG
PET/CT may be used for the indication or diagnosis of IgG4-
RD. 18F-FDG PET/CT also aids in the selection of biopsy site
and guiding the recanalization of ureteral obstruction. More-
over, this method is valuable for early response monitoring to
achieve personalized treatment of the disease. A rapid, signif-
icant response to steroid-based therapy may also help verify
the diagnosis and exclude possible malignancies. Therefore,
18F-FDG PET/CT is a useful tool that has a potential to
uncover more details and provide a better understanding of
IgG4-RD. Further confirmation in patients suspected to have
IgG4-RD is needed, and when proven useful in differentiation
with malignancies, especially lymphoma, these image charac-
teristics of 18F-FDG PET/CT should be updated into the
consensus diagnostic criteria for IgG4-RD.
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